Learn about the rising threat of antibiotic-resistant bacteria in HIV patients in Ethiopia and the need for improved ...

A strain of the bacterium Klebsiella pneumoniae isolated from an 86-year-old woman with a urinary infection admitted to ...

Among children treated with an oral agent, the recurrence rate was 16/42 (38.1%) following penicillin or amoxicillin and 10/36 (27.8%) following a beta-lactamase resistant agent (adjusted odds ...

This rate is higher than observed in children treated with a beta-lactamase resistant agent, although the associated risk estimate reached statistical significance (pooled OR: 2.39 [95% CI ...

This particular strain of Klebsiella pneumoniae had previously been detected in the United States. The bacterium frequently causes infections in hospitals, is not eliminated by any existing antibiotic ...

The drug – a combination of beta-lactam antibiotic aztreonam with beta-lactamase inhibitor avibactam – is the first drug of this type to get a green light from the European Commission to treat ...

A strain of the bacterium Klebsiella pneumoniae isolated from an 86-year-old woman with a urinary infection admitted to ...

Venatorx meanwhile is developing a pipeline of novel combinations of beta-lactam antimicrobials and beta-lactamase inhibitors – drugs used alongside the antibiotics to prevent resistance – for ...

Jointly developed by Pfizer and Abbvie, Emblaveo combines a beta-lactam antibiotic (aztreonam) with a beta-lactamase inhibitor (avibactam). The combination aims to restore aztreonam's activity against ...

The US Food and Drug Administration (FDA) has approved Iterum Therapeutics' new drug application (NDA) for ORLYNVAH ...